Hua-Jay J Cherng, MD

Hua-Jay Cherng, MD, suggested molecular genotyping could replace standard R-CHOP with targeted, less toxic treatments tailored to specific DLBCL subtypes.

Hua-Jay Cherng, MD, described the “threefold” benefits of taking part in training programs among junior investigators in lymphoma.

Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.